<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098159</url>
  </required_header>
  <id_info>
    <org_study_id>Surveillance of an A-V access</org_study_id>
    <nct_id>NCT04098159</nct_id>
  </id_info>
  <brief_title>Role of Regular Surveillance on Maintenance of Patency of an Arteriovenous Access</brief_title>
  <official_title>Role of Regular Surveillance on Maintenance of Patency of an Arteriovenous Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Kidney disease (CKD) is a worldwide public health problem that classified into five
      stages (1). End stage renal disease (CDK stage 5) patients require a well-functioning
      vascular access (VA) for successful hemodialysis treatment (2). Types of VA include
      arteriovenous fistulae (AVFs) and arteriovenous grafts (AVGs). A vascular access is liable to
      early or late complications, and ultimately access failure. A meta-analysis showed that a 17%
      mean early access failure However recent studies have shown higher failure rates of up to
      46%, with one year patencies between 52% to 83% (3). Low VA flow, thrombosis and loss of
      patency may result in under-dialysis that leads to increased morbidity, mortality and
      healthcare expenditure (4). In the majority of VAs, stenoses develop over variable intervals
      causing VA thrombosis and failure (5). If early detected and corrected, VA function and
      patency can be preserved and under-dialysis can be minimized or avoided. The aim of this
      study is to find out the role of periodic surveillance of VA in the detection of VA
      dysfunction and correctable lesions that may necessitate pre-emptive interventions to
      maintain VA patency and prevent VA loss
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number, type and technical success rate for elective interventions</measure>
    <time_frame>within one year of creation of the VA</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>secondary patency rate of the Arteriovenous Access after elective intervention</measure>
    <time_frame>within one year of creation of the VA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number , type of complication that resulted from elective interventions</measure>
    <time_frame>within one year of creation of the VA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>primary patency rate of newly created Arteriovenous Access in assiut governorate</measure>
    <time_frame>within one year of creation of the VA</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hemodialysis Access Failure</condition>
  <arm_group>
    <arm_group_label>ESRD Patients have functioning or failing VAs (AVFs or AVGs).</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>duplex ultrasound</intervention_name>
    <description>regular duplex follow up every three months with subsequent intervention either diagnostic venography , angioplasty or surgery according to the type of the lesion</description>
    <arm_group_label>ESRD Patients have functioning or failing VAs (AVFs or AVGs).</arm_group_label>
    <other_name>diagnostic venography</other_name>
    <other_name>angioplasty</other_name>
    <other_name>surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ESRD Patients have functioning or failing VAs (AVFs or AVGs).

        Exclusion Criteria:

          -  ESRD patients have infected or failed VAs .

          -  patientrefusal .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ahmed m rashed, resident</last_name>
    <phone>00201064252719</phone>
    <email>ahmedrashed9933@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Gray RJ, Sacks D, Martin LG, Trerotola SO. Reporting standards for percutaneous interventions in dialysis access. Technology Assessment Committee. J Vasc Interv Radiol. 1999 Nov-Dec;10(10):1405-15. Review.</citation>
    <PMID>10584659</PMID>
  </reference>
  <reference>
    <citation>Lee T, Mokrzycki M, Moist L, Maya I, Vazquez M, Lok CE; North American Vascular Access Consortium. Standardized definitions for hemodialysis vascular access. Semin Dial. 2011 Sep-Oct;24(5):515-24. doi: 10.1111/j.1525-139X.2011.00969.x. Epub 2011 Sep 9. Review.</citation>
    <PMID>21906166</PMID>
  </reference>
  <reference>
    <citation>National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.</citation>
    <PMID>11904577</PMID>
  </reference>
  <reference>
    <citation>Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis. 1994 May;23(5):661-9.</citation>
    <PMID>8172208</PMID>
  </reference>
  <reference>
    <citation>Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, Kooman J, Martin-Malo A, Pedrini L, Pizzarelli F, Tattersall J, Vennegoor M, Wanner C, ter Wee P, Vanholder R. EBPG on Vascular Access. Nephrol Dial Transplant. 2007 May;22 Suppl 2:ii88-117.</citation>
    <PMID>17507428</PMID>
  </reference>
  <reference>
    <citation>Besarab A. Advances in end-stage renal diseases 2000. Access monitoring methods. Blood Purif. 2000;18(4):255-9. Review.</citation>
    <PMID>10965064</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>September 21, 2019</last_update_submitted>
  <last_update_submitted_qc>September 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohammed Rashed</investigator_full_name>
    <investigator_title>resident of vascular surgery</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

